Everest Medicines Limited
雲頂新耀有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 1952)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON THE APPROVAL OF NEW DRUG APPLICATION IN CHINA FOR XERAVA™ FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULT PATIENTS

This announcement is made by Everest Medicines Limited (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update.

The board of directors of the Company (the "**Board**") is pleased to announce that the National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA) for Xerava™(eravacycline) for the treatment of complicated intra-abdominal infections ("**cIAI**") in adult patients in China.

Xerava™ has been approved and commercialized in Singapore. It was also approved in Hong Kong and is currently under regulatory review for cIAI in the Taiwan region. Since 2020, Xerava™ has been recommended in multiple global treatment guidances issued by the Infectious Disease Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) as a treatment choice for multidrug resistant gram-negative bacterial infections, including carbapenem resistant organisms. In addition, it was included in an expert consensus on the multidisciplinary management of intra-abdominal infections by the Chinese Society of Surgery of Chinese Medical Association, the Infectious Diseases Society for Evidence-based and Translational Medicine of Chinese Research Hospital Association and the Editorial Board of Chinese Journal of Surgery. In February 2023, Xerava™ was also recommended in the "Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli".

INFORMATION ABOUT COMPLICATED INTRA-ABDOMINAL INFECTIONS

cIAI is a type of major hospital- or community-acquired infection which extends beyond the source organ into the peritoneal space and can result from perforation of or damage to the gastrointestinal tract. cIAI diagnoses include intra-abdominal abscess, stomach or intestinal perforation, peritonitis, appendicitis, cholecystitis, or diverticulitis. cIAI is caused by different bacterial pathogens, including gram-negative aerobic bacteria, gram-positive bacteria, and anaerobic bacteria. In 2018, there were 2.9 million cIAI patients in China alone, with increasing rates of infections caused by drug-resistant bacteria, which limits the effectiveness of currently available antibiotics.

INFORMATION ABOUT XERAVA™ (ERAVACYCLINE)

Xerava™ (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against gram-negative and gram-positive pathogens that have acquired multidrug resistance and are prevalent in China. Xerava™ is currently approved for the treatment of cIAI in the United States of America, the European Union, the United Kingdom, Singapore and Hong Kong and the medicine is currently under review for the treatment of cIAI in Taiwan. Xerava™ was licensed from Tetraphase Pharmaceuticals Inc., now a wholly-owned subsidiary of Innoviva, Inc.

Cautionary statement: We cannot guarantee that we will be able to develop, or ultimately market, Xerava™ (eravacycline) successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Hong Kong, 17 March 2023

As at the date of this announcement, the Board comprises Mr. Wei Fu as Chairman and Executive Director, Mr. Yongqing Luo, Mr. Ian Ying Woo and Mr. Xiaofan Zhang as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.